Canaccord analyst William Plovanic lowered the firm’s price target on Edwards Lifesciences to $66 from $77 and keeps a Buy rating on the shares. The firm updatied its model post the sale of critical care business and commentary from September investor conferences. Canaccord believes 2025 is expected to be a transition year for EW post the sale of the Critical Care business to Becton Dickinson in early September 2024 for $4.2B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $70 from $76 at Evercore ISI
- Edwards Lifesciences price target lowered to $77 from $83 at Citi
- Eyes on Fed ahead of expected interest rate cut: Morning Buzz
- Nvidia, ARM initiated: Wall Street’s top analyst calls
- Edwards Lifesciences downgraded to Hold from Buy at Jefferies